IDYA · IDEAYA Biosciences, Inc.
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-07-07 | Ruiz Briseno Andres |
See Remarks |
Sell↓
Filing footnotes — Common Stock (Direct)
The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on December 19, 2025. This transaction was executed in multiple trades in prices ranging from $40.00 to $40.10, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
Common Stock
|
9,550 |
| 2026-07-07 | Ruiz Briseno Andres |
See Remarks |
Convert↑
|
Common Stock
|
9,550 |
| 2026-07-07 | Ruiz Briseno Andres |
See Remarks |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
100% of the shares subject to the option is fully vested and exercisable. |
Stock Option (Right to Buy)
|
9,550 |
| 2026-06-16 | ROSEN TERRY J |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. |
Stock Option (right to buy)
|
20,000 |
| 2026-06-16 | Stein Jeffrey |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. |
Stock Option (right to buy)
|
20,000 |
| 2026-06-16 | Hampton Malcolm Garret |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. |
Stock Option (right to buy)
|
20,000 |
| 2026-06-16 | YARNO WENDY L |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. |
Stock Option (right to buy)
|
20,000 |
| 2026-06-16 | MACKEY CATHERINE J |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. |
Stock Option (right to buy)
|
20,000 |
| 2026-06-16 | Morrison Scott W |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. |
Stock Option (right to buy)
|
20,000 |
| 2026-03-02 | Stein Jeffrey |
Director |
Buy↑
Filing footnotes — Common Stock (Direct)
This transaction was executed in multiple trades in prices ranging from $32.743 to $33.1999, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote. |
Common Stock
|
50,000 |
| 2026-01-30 | Bleharski Joshua |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
25% of the shares subject to the option vest on the first anniversary measured from January 1, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. |
Stock Option (right to buy)
|
170,000 |
| 2026-01-30 | Beaupre Darrin |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
25% of the shares subject to the option vest on the first anniversary measured from January 1, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. |
Stock Option (right to buy)
|
175,000 |
| 2026-01-30 | Hata Yujiro S |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
25% of the shares subject to the option vest on the first anniversary measured from January 1, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. |
Stock Option (right to buy)
|
600,000 |
| 2026-01-30 | Snyder Douglas B. |
SVP, General Counsel |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
25% of the shares subject to the option vest on the first anniversary measured from January 1, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. |
Stock Option (right to buy)
|
130,000 |
| 2026-01-30 | DORMAN STUART |
Chief Commercial Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
25% of the shares subject to the option vest on the first anniversary measured from January 1, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. |
Stock Option (right to buy)
|
155,000 |
| 2026-01-30 | Ruiz Briseno Andres |
See Remarks |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
25% of the shares subject to the option vest on the first anniversary measured from January 1, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. |
Stock Option (right to buy)
|
80,000 |
| 2026-01-30 | WHITE MICHAEL ANTHONY |
Chief Scientific Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
25% of the shares subject to the option vest on the first anniversary measured from January 1, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. |
Stock Option (right to buy)
|
190,000 |
| 2025-11-28 | Ruiz Briseno Andres |
See Remarks |
Award↑
Filing footnotes — Common Stock (Direct)
The shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
Common Stock
|
1,253 |
| 2025-11-28 | Snyder Douglas B. |
SVP, General Counsel |
Award↑
Filing footnotes — Common Stock (Direct)
The shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
Common Stock
|
1,041 |
| 2025-06-24 | Hampton Malcolm Garret |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. |
Stock Option (right to buy)
|
20,000 |
| 2025-06-24 | ROSEN TERRY J |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. |
Stock Option (right to buy)
|
20,000 |
| 2025-06-24 | MACKEY CATHERINE J |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. |
Stock Option (right to buy)
|
20,000 |
| 2025-06-24 | YARNO WENDY L |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. |
Stock Option (right to buy)
|
20,000 |
| 2025-06-24 | Morrison Scott W |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. |
Stock Option (right to buy)
|
20,000 |
| 2025-06-24 | Stein Jeffrey |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. |
Stock Option (right to buy)
|
20,000 |
| 2025-05-30 | Snyder Douglas B. |
SVP, General Counsel |
Award↑
Filing footnotes — Common Stock (Direct)
The shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
Common Stock
|
1,039 |
| 2025-02-27 | Ruiz Briseno Andres |
See Remarks |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
25% of the shares subject to the option vest on the first anniversary measured from January 1, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. |
Stock Option (right to buy)
|
75,000 |
| 2025-02-27 | Beaupre Darrin |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
25% of the shares subject to the option vest on the first anniversary measured from January 1, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. |
Stock Option (right to buy)
|
185,000 |
| 2025-02-27 | Snyder Douglas B. |
SVP, General Counsel |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
25% of the shares subject to the option vest on the first anniversary measured from January 1, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. |
Stock Option (right to buy)
|
33,000 |
| 2025-02-27 | WHITE MICHAEL ANTHONY |
Chief Scientific Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
25% of the shares subject to the option vest on the first anniversary measured from January 1, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. |
Stock Option (right to buy)
|
185,000 |
| 2025-02-27 | Hata Yujiro S |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
25% of the shares subject to the option vest on the first anniversary measured from January 1, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. |
Stock Option (right to buy)
|
600,000 |
| 2025-02-27 | DORMAN STUART |
Chief Commercial Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
25% of the shares subject to the option vest on the first anniversary measured from January 1, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. |
Stock Option (right to buy)
|
15,000 |
| 2025-02-18 | Hata Yujiro S |
Director |
Convert↑
|
Common Stock
|
12,808 |
| 2025-02-18 | Hata Yujiro S |
Director |
Convert↓
Filing footnotes — Stock Option (right to buy) (Direct)
The shares subject to the option are fully vested and exercisable. |
Stock Option (right to buy)
|
12,808 |
| 2024-11-29 | Ruiz Briseno Andres |
See Remarks |
Award↑
Filing footnotes — Common Stock (Direct)
The shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
Common Stock
|
682 |
| 2024-09-26 | Snyder Douglas B. |
SVP, General Counsel |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
25% of the shares subject to the option vest on the first anniversary measured from September 18, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. |
Stock Option (Right to Buy)
|
140,000 |
| 2024-09-18 | Snyder Douglas B. |
SVP, General Counsel |
Other↑
|
No Securities Owned
|
0 |
| 2024-06-27 | Throne Jason |
Chief Legal Officer |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
25% of the shares subject to the option vest on the first anniversary measured from July 1, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. |
Stock Option (Right to Buy)
|
6,424 |
| 2024-06-27 | Throne Jason |
Chief Legal Officer |
Convert↑
|
Common Stock
|
47,060 |
| 2024-06-27 | Throne Jason |
Chief Legal Officer |
Convert↑
|
Common Stock
|
6,424 |
| 2024-06-27 | Throne Jason |
Chief Legal Officer |
Convert↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option are fully vested and exercisable. |
Stock Option (Right to Buy)
|
47,060 |
| 2024-05-31 | Morrison Scott W |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. |
Stock Option (right to buy)
|
16,200 |
| 2024-05-31 | YARNO WENDY L |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. |
Stock Option (right to buy)
|
16,200 |
| 2024-05-31 | Stein Jeffrey |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. |
Stock Option (right to buy)
|
16,200 |
| 2024-05-31 | Hampton Malcolm Garret |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. |
Stock Option (right to buy)
|
16,200 |
| 2024-05-31 | ROSEN TERRY J |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. |
Stock Option (right to buy)
|
16,200 |
| 2024-05-31 | MACKEY CATHERINE J |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. |
Stock Option (right to buy)
|
16,200 |
| 2024-05-31 | Kelley Susan L. |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. |
Stock Option (right to buy)
|
16,200 |
| 2024-05-29 | WHITE MICHAEL ANTHONY |
Chief Scientific Officer |
Convert↑
|
Common Stock
|
28,500 |
| 2024-05-29 | WHITE MICHAEL ANTHONY |
Chief Scientific Officer |
Convert↓
Filing footnotes — Stock Option (right to buy) (Direct)
25% of the shares subject to the option vest on the first anniversary measured from January 1, 2022 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. |
Stock Option (right to buy)
|
28,500 |